Carriage of antimicrobial resistant Escherichia coli in dogs: prevalence, associated risk factors and molecular characteristics by Wedley, Amy L et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Carriage of antimicrobial resistant Escherichia coli in dogs:
prevalence, associated risk factors and molecular characteristics
Citation for published version:
Wedley, AL, Dawson, S, Maddox, TW, Coyne, KP, Pinchbeck, G, Clegg, PD, Nuttall, T, Kirchner, M &
Williams, N 2016, 'Carriage of antimicrobial resistant Escherichia coli in dogs: prevalence, associated risk
factors and molecular characteristics', Veterinary Microbiology, vol. 199, pp. 23-30.
https://doi.org/10.1016/j.vetmic.2016.11.017
Digital Object Identifier (DOI):
10.1016/j.vetmic.2016.11.017
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
Veterinary Microbiology
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 11. May. 2020
Accepted Manuscript
Title: Carriage of antimicrobial resistant Escherichia coli in
dogs: Prevalence, associated risk factors and molecular
characteristics
Author: Amy L. Wedley Susan Dawson Thomas W. Maddox
Karen P. Coyne Gina L. Pinchbeck Peter Clegg Tim Nuttall
Miranda Kirchner Nicola J. Williams
PII: S0378-1135(16)30666-6
DOI: http://dx.doi.org/doi:10.1016/j.vetmic.2016.11.017
Reference: VETMIC 7445
To appear in: VETMIC
Received date: 8-9-2015
Revised date: 6-11-2016
Accepted date: 16-11-2016
Please cite this article as: Wedley, Amy L., Dawson, Susan, Maddox, Thomas
W., Coyne, Karen P., Pinchbeck, Gina L., Clegg, Peter, Nuttall, Tim, Kirchner,
Miranda, Williams, Nicola J., Carriage of antimicrobial resistant Escherichia coli
in dogs: Prevalence, associated risk factors and molecular characteristics.Veterinary
Microbiology http://dx.doi.org/10.1016/j.vetmic.2016.11.017
This is a PDF file of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that
apply to the journal pertain.
Carriage of antimicrobial resistant Escherichia coli in dogs: prevalence, associated risk 
factors and molecular characteristics. 
 
Amy L. Wedley
1
, Susan Dawson
2
, Thomas W. Maddox
3
, Karen P. Coyne
1
, Gina L 
Pinchbeck
1
, Peter Clegg
4
, Tim Nuttall
2,5
, Miranda Kirchner
6
, Nicola J. Williams
1
. 
 
1
Department of Epidemiology and Population Health, Institute of Infection and Global 
Health, Leahurst Campus, University of Liverpool, UK, CH64 7TE 
2
School of Veterinary Science, Leahurst Campus, University of Liverpool, UK, CH64 7TE 
3
Small Animal Teaching Hospital, Leahurst Campus, University of Liverpool, UK, CH64 
7TE 
4
Department of Musculoskeletal Biology, Institute of Ageing and Chronic Disease, Leahurst 
Campus, University of Liverpool, UK, CH64 7TE 
5
Royal (Dick) School of Veterinary Studies, University of Edinburgh, Easter Bush Campus, 
Roslin, UK, EH25 9RG (current address). 
6
Animal and Plant Health Agency, Department of Bacteriology, Woodham lane, New Haw, 
Surrey, KT15 3NB  
  
Correspondence:   Professor Nicola Williams 
    Department of Epidemiology and Population Health Research, 
Institute of Infection and Global Health,    
Leahurst Campus,  
University of Liverpool,  
UK,  
CH64 7TE 
 
Email:    njwillms@liverpool.ac.uk  
Telephone/ fax:  0151 795 6051/ 0151 794 6005 
  
Research Highlights 
 Antimicrobial resistant (AMR) E. coli from faeces of vet-visiting dogs were common. 
 Risk factors for carriage include antimicrobial use and consuming raw poultry meat. 
 Resistance genes identified are also common in isolates of human origin. 
 Dogs may be a reservoir of AMR bacteria, having public health implications. 
 
  
Abstract 
Resistance to antimicrobials, in particular that mediated by extended spectrum β-lactamases 
(ESBL) and AmpC β-lactamases are frequently reported in bacteria causing canine disease as 
well as in commensal bacteria, which could be a potential health risk for humans they come 
into contact with. This cross-sectional study aimed to estimate the prevalence and investigate 
the molecular characteristics of ESBL and plasmid encoded AmpC (pAmpC)-producing E. 
coli in the mainland UK vet-visiting canine population and, using responses from detailed 
questionnaires identify factors associated with their carriage. Faecal samples were cultured 
for antimicrobial resistant (AMR), ESBL and pAmpC-producing E. coli. A subset of ESBL 
and pAmpC-producing isolates were subjected to multi-locus sequence typing and DNA 
microarray analyses. Multivariable logistic regression analysis was used to construct models 
to identify risk factors associated with multidrug resistant (MDR, resistance to three or more 
antimicrobial classes), fluoroquinolone resistance, ESBL and AmpC-producing E. coli. AMR 
E.coli were isolated from 44.8% (n=260) of samples, with 1.9% and 7.1% of samples 
carrying ESBL and pAmpC-producing E. coli, respectively. MDR E. coli were identified in 
18.3% of samples. Recent use of antimicrobials and being fed raw poultry were both 
identified as risk factors in the outcomes investigated. A number of virulence and resistance 
genes were identified, including genes associated with extra-intestinal and enteropathogenic 
E. coli genotypes. Considering the close contact that people have with dogs, the high levels of 
AMR E. coli in canine faeces may be a potential reservoir of AMR bacteria or resistance 
determinants.  
1. Introduction 
Antimicrobial resistant (AMR) bacteria is a common and increasing problem in healthcare 
and community settings. Multidrug resistant bacteria, for example Escherichia coli, are 
commonly reported in dogs and other companion animals (Shaheen et al., 2010). In addition 
to E. coli being a common cause of gastrointestinal infections, the vast majority of humans, 
dogs and other mammals carry commensal E. coli within the gut. However, such commensal 
bacteria may also cause opportunistic disease if outside their normal niche, for example in the 
urinary tract (Johnson and Russo, 2002). Furthermore, the location of commensal E. coli 
means that they are exposed to the selective pressure of antimicrobials given orally. These 
commensal bacteria may then themselves act as a reservoir for such resistance determinants. 
As such, E. coli isolated from faecal samples can provide a good indication of the reservoir of 
resistance within the gut flora (van den Bogaard and Stobberingh, 2000).  
One resistance mechanism of particular concern is that mediated by extended spectrum β-
lactamases (ESBLs), which  hydrolyse third generation cephalosporins, such as ceftazidime, 
cefotaxime, cefpodoxime and ceftiofur (Livermore, 2008). E. coli harbouring such ESBL 
encoding genes have become increasingly prevalent in hospitals and in the community in 
people (Brolund et al., 2014) and dogs (Gandolfi-Decristophoris et al., 2013). Plasmid 
mediated AmpC (pAmpC) enzymes, which also have a broad spectrum of resistance to 
cephalosporins, but are resistant to β-lactamase inhibitors, have also been documented in 
dogs (Sidjabat et al., 2006).  
While AMR E. coli from canine clinical samples has been reported (Pedersen et al., 2007), 
the general human population is more likely to be exposed to the bacteria present in the 
faeces of dogs. For example, owners picking up after their dogs have defecated. It is therefore 
important to understand the prevalence of antimicrobial resistance among the E. coli resident 
in the gut of healthy dogs. Such studies have been carried out in both Europe (SVARM, 
2006) and Canada (Murphy et al., 2009) and have demonstrated that animals and humans 
often carry the same resistance determinants. A small number of studies have shown, using 
macro-restriction pulsed-field gel electrophoresis, that dogs, cats and humans in the same 
household can have identical bacteria (Johnson et al., 2008a), supporting the suggestion of 
transmission of enteric bacteria between humans and their pets. However, studies that 
investigate the risk factors for carriage of AMR bacteria are very limited and focus mainly on 
acquisition of antimicrobial resistance during hospitalisation (Gibson et al., 2011; Leite-
Martins et al., 2014). Identification of such risk factors could be key in developing effective 
strategies to reduce the development and spread of such resistance in the future. 
The aim of this study was to determine the faecal prevalence of AMR E. coli, including 
ESBL and pAmpC β-lactamase producing E. coli, in the mainland UK vet-visiting dog 
community. DNA micro array analysis was used on a subset of multi drug resistant (MDR, 
resistant to three or more antimicrobial classes), and ESBL producing isolates to investigate 
the presence of genes associated with antimicrobial resistance and virulence. In addition, risk 
factors associated with carriage of antimicrobial resistance were determined.  
2. Materials and Methods 
2.1. Study population 
Dogs visiting veterinary practices in mainland UK were recruited during consultation with 
their clinician. Practices were randomly selected from those listed in the 2006 RCVS 
directory of veterinary practices who indicated that they treated dogs. Hospitalised dogs were 
excluded. An estimated sample size of 555 dogs was based on the participation of 50 
practices, an expected carriage rate of AMR E. coli of 50%, 5% precision, 95% confidence 
intervals and a conservative between practice variance of 0.01. To allow for a degree of non-
compliance, each practice was asked to recruit 28 dogs. A further 37 practices were 
subsequently recruited due to the low numbers of dogs enrolled by some practices. Dogs 
were recruited to the study between April 2008 and July 2009. Consent was obtained, from 
the owners, by the clinician during their routine consultation before any samples were 
collected. Ethical approval was granted by the University of Liverpool Committee on 
Research Ethics (Reference RETH000118).  
2.2. Sample collection and questionnaire 
Owners were provided with a sterile collection tube and gloves to collect a fresh faecal 
sample from their dog. They were also asked to complete a six-page questionnaire with both 
tick box and free text questions. The questionnaire included questions relating to signalment, 
medical history of the dog over the previous three months (including use of antimicrobials), 
diet and recent use of antimicrobials by any other family member (including other pets). The 
faecal sample and completed questionnaire were returned by first class post. 
2.3. Sample processing 
An equal volume of the faecal sample was added to 5 ml of brain heart infusion broth with 
5% glycerol (BHIG) and mixed thoroughly to create a faecal homogenate. A portion of this 
was stored below -70 °C and the remainder used to isolate AMR E. coli, as previously 
described (Wedley et al., 2011).  Briefly, the faecal homogenate was plated directly onto 
MacConkey and eosin methylene blue agar (EMBA) and antimicrobial discs (MAST group 
Ltd) applied to the surface: ampicillin (10 µg); amoxicillin clavulanic acid (30 µg); 
chloramphenicol (30 µg); ciprofloxacin (1 µg); nalidixic acid (30 µg); tetracycline (30 µg); 
and trimethoprim (2.5 µg). Following overnight incubation at 37°C, colonies 
morphologically consistent with E. coli within the zone of inhibition around the antimicrobial 
discs were selected. One isolate, if present, from within the zone of each of the seven 
antimicrobial discs was selected. For screening of samples for ESBL producing E. coli, two 
EMBA plates, one containing cefotaxime (1 μg/ml) and the other ceftazidime (1 μg/ml), were 
streaked with the faecal homogenate. If present, at least one isolate morphologically 
consistent with E. coli was selected from each plate. If no growth consistent with E. coli 
occurred, further EMBA plates were streaked with faecal homogenate following overnight 
enrichment in buffered peptone water. In addition, for non-selective isolation of E. coli, an 
EMBA plate containing no antimicrobials was streaked with the faecal homogenate. Three 
isolates morphologically consistent with E. coli were selected for antimicrobial susceptibility 
testing. Therefore, it was possible to select a total of 19 isolates from each sample. The 
identity of E. coli isolates was confirmed by biochemical testing and a PCR assay to detect 
the uidA gene (McDaniels et al., 1996). 
2.4. Antimicrobial susceptibility testing 
Antimicrobial disc susceptibility testing following British Society for Antimicrobial 
Chemotherapy (BSAC) guidelines (Andrews, 2007) was performed on all isolates using the 
same antimicrobial discs as used for the isolation of E. coli above. Additionally, for potential 
ESBL or AmpC producing E. coli, an extended panel of antimicrobial discs were used: 
aztreonam (30µg), ceftazidime (30µg), ceftriaxone (30µg), cefoxitin (30µg), cefuroxime 
(30µg), cefalexin (30µg), tazobactam (10µg), piperacillin (75µg) and trimethoprim-
sulfamethoxazole (25µg). The reference strain E. coli ATCC 25922 was used as a fully 
sensitive control in all testing. Following overnight incubation at 37°C, the zone diameters in 
mm were recorded. For each sample, only one isolate per unique resistance phenotype was 
included in any subsequent testing.  
2.5. Phenotypic confirmation of ESBL production  
The paired disc diffusion test (MAST Group Ltd) was performed on isolates suspected of 
ESBL production, selected from the EMBA plates containing ceftazidime or cefotaxime.  
Following overnight incubation, the zone diameters in mm were recorded. Production of an 
ESBL by an isolate was confirmed if the zone diameter was expanded by at least 5mm in the 
presence of clavulanic acid. When an isolate showed resistance to a cephalosporin, with a 
difference in zone diameter less than 5mm this suggested the production of an AmpC β-
lactamase, both an ESBL and an AmpC β-lactamase, or an inhibitor resistant ESBL. 
2.6. Characterisation of ESBL and blaAmpC genes 
PCR was used to detect the presence of blaTEM, blaSHV, blaCTX-M and plasmid encoded 
blaAmpC genes as previously described (Batchelor et al., 2005; Boyd et al., 2004; Essack et al., 
2001; Perez-Perez and Hanson, 2002). For blaCTX-M positive isolates, assignment of the 
specific blaCTX-M gene group was carried out (Batchelor et al., 2005; Boyd et al., 2004), 
followed by sequencing of the PCR amplicon. For blaCMY positive isolates, the gene was 
amplified (Liebana et al., 2004), with an additional set of internal primers (CITMf and 
CITMr) used for sequencing (Perez-Perez and Hanson, 2002). All sequences were compared 
to those submitted to GenBank (http://www.ncbi.nlm.nih.gov/genbank/) to determine the 
specific blaCTX-M or blaCMY gene. In all PCRs, a positive control, known to harbour the target 
gene in previous PCR assays, was included.  
2.7. DNA microarray analysis of E. coli 
Isolates for DNA microarray analysis were chosen due to their phenotypic resistance to 
multiple classes of antimicrobials and included all isolates positive for carriage of a blaCTX-M 
gene and a selection of those carrying blaTEM and/or plasmid encoded blaAmpC genes. These 
E. coli isolates were subjected to DNA microarray based chip analysis using Alere E. coli and 
Alere AMR–ve  chips according to the manufacturer’s instructions (Alere Technologies, 
Jena, Germany). Alere E. coli array detects the presence of virulence associated E. coli genes. 
Alere AMR-ve detects the presence of genes responsible for resistance to a selection of 
antimicrobials in Gram negative bacteria. 
2.8. Multi-Locus Sequence Typing analysis of E. coli 
Multi-locus sequence typing (MLST) of the isolates selected for DNA microarray analysis 
was carried out as previously described (Wirth et al., 2006), http://mlst.ucc.ie/mlst/dbs/Ecoli.  
2.9. Statistical analysis 
Four different outcomes (fluoroquinolone resistance, MDR, ESBL-producing E. coli and 
pAmpC-producing E. coli) were tested for associations with explanatory variables 
(questionnaire responses) using univariable logistic regression. In all models, clustering at the 
practice level was taken into account by including the practice as a mixed effect in the models 
constructed. A likelihood ratio test (LRT) comparing the models with and without each of the 
explanatory variables was performed. Associations were considered statistically significant if 
P<0.05. For variables with small numbers, categories were grouped together. Also, the 
reference category was changed if this was considered appropriate. For example, for length of 
prescription of antimicrobials, “none prescribed” was made the reference category. For 
variables with zero cells, a Fisher’s exact test was carried out to determine if there was a 
significant association between the outcome and the response variable. If significant, a false 
positive was added to the dataset for the purposes of construction of a multivariable model. A 
multivariable model was constructed including all those variables with a P-value less than 
0.3. Backwards elimination was used where removal of each variable from the full model as 
assessed by the likelihood ratio test and the variable with the highest P-value was removed. 
This process was repeated until only those variables whose removal resulted in a LRT P-
value of less than 0.05 remained. Each variable that had been removed was then sequentially 
added back in and a LRT performed to test whether the variable should remain in the final 
model. Where the final model included more than two variables, tests for interactions 
between the variables were carried out and interactions with P-value of less than 0.05 were 
retained in the final model. Multivariable analysis excluded any dogs that did not have 
complete responses for any of the variables included in the model. Statistical analyses were 
performed using the R base, lme4, and lmtest packages.  
To determine the intraclass correlation coefficient (the measure of clustering of an outcome 
within practices), the latent variable approach was used (Goldstein et al., 2002) with equation 
1 below. 
 
         
                 
                  
  
 
 (Equation 1) 
3. Results 
3.1. Study population 
In total, 580 faecal samples, 574 with questionnaires, were returned but only 445 
questionnaires were completed fully. The median age of dogs recruited was 5 years (range 6 
weeks to 17 years) and 64 different pure breeds were represented. Cross-breeds (n=123, 
21.4%), followed by Labrador retrievers (n=90, 15.7%) were most common. 
3.2. Prevalence of antimicrobial resistance 
At least one E. coli was isolated from 561 (96.7%) of the 580 faecal samples, with AMR E. 
coli isolated from 260 (44.8%) faecal samples. A total of 436 unique E. coli isolates (up to 
nine per sample) were recovered based on their antimicrobial susceptibility profile. Table 1 
shows the simple sample prevalence of faecal carriage of AMR E. coli and the prevalence 
adjusted for clustering. The most common resistance phenotypes observed were to ampicillin 
(37.2%), tetracycline (30.0%) and trimethoprim (23.8%). E. coli resistant to 
amoxicillin/clavulanic acid, chloramphenicol, ciprofloxacin and nalidixic acid was observed 
in less than 10% of dogs. MDR E. coli was isolated from 18.3% of dogs. The intraclass 
correlation coefficient (ICC) of presence of ESBL and pAmpC genes (53.5% and 19.9% 
respectively) among E. coli  is much higher than for resistance to the other antimicrobials 
(between 0 and 10%), suggesting some degree of clustering at the practice level for these 
outcomes.  
ESBL producing E. coli were isolated from 1.9% of samples and a pAmpC β-lactamase 
producing E. coli from 7.1% of samples. Fifty-two isolates from fifty dogs (8.6% of samples) 
were identified as either ESBL or pAmpC producers by phenotypic testing and PCR.  In these 
isolates, resistance to ampicillin, cephalexin and cefoxitin (8 isolates) was most common. All 
but four isolate were susceptible to aztreonam. MDR was observed in 13 of the 52 isolates 
(25%). 
3.3. Characterisation of ESBL and AmpC β-lactamase genes 
Of the 58 isolates obtained from the cephalosporin containing plates, 21 carried a blaTEM 
gene. However, six of these were not resistant to third generation cephalosporins in disc 
diffusion testing and are therefore most likely to be blaTEM-1. Ten carried a blaCTX-M gene 
(Table 2), most of which belonged to CTX-M group 1 (five blaCTX-M-1, two blaCTX-M-15 and 
one blaCTX-M-3). One isolate carried blaCTX-M-14/18 (CTX-M group 9) and one blaCTX-M-20 (CTX-
M group 2). A plasmid encoded blaAmpC gene was found in 42 isolates, which were all shown 
to be blaCMY-2.  No isolates carried a blaSHV gene.  
3.4. Microarray analysis of E. coli 
A subset of 30 isolates underwent microarray analysis. These included all ten isolates 
harbouring a blaCTX-M gene and a selection of isolates harbouring one or both of blaTEM or 
blaAmpC. The results observed with AMR array chip showed good agreement with in vitro 
testing of antimicrobial susceptibility (Figure 1). Of the 30 isolates tested, 23 harboured 
genes encoding resistance to tetracycline (tet(A) and tet(B) and 20 harboured genes encoding 
resistance to trimethoprim (dfrA1, dfrA7, dfr12, dfrA17 and dfrA5). Genes encoding 
resistance to aminoglycosides were also identified in 25 isolates (aadA1, aadA2, aadA4, 
aac3Iva, aac6lb, strA and strB), whilst 24 isolates harboured genes encoding resistance to 
sulphonamides (sul1 and sul2). Seven isolates harboured genes encoding resistance to 
chloramphenicol (catA1, catB3 and floR). Erythromycin resistance genes (ere(A) and erm(B)) 
were identified in a single isolate. A number of resistance genes appeared to be clustered 
within isolates. For example, there was a positive correlation between trimethoprim 
resistance genes dfrA19 and dfrA17 and the aminoglycosidase gene aadA4. Correlation was 
also evident between the aminoglycosidase genes strA and strB and the sulphonamide 
resistance gene sul2. Supplementary figure F1 provides further detail of the clustering present 
between resistance genes in the isolates investigated.  
 Twenty-three different genes associated with virulence were detected.  Ten or isolates were 
found to be positive for iss (22 isolates) associated with increased resistance to serum, 
followed by iroN (14 isolates) associated with iron uptake, lpfA (11 isolates) encoding long 
polar fimbriae and mchF (10 isolates) encoding a subunit of an ABC transporter protein. The 
full list of virulence genes identified is provided in supplementary table S1. A number of 
genes associated with the locus of enterocyte effacement (LEE) were detected in eight 
isolates, though none appeared to possess all genes encoded by the pathogenicity island.  
3.5. Multi-Locus Sequence Typing 
The 31 isolates studied by microarray also underwent multi-locus sequence typing, although 
seven could not be typed due to poor sequence quality, or because no amplicon could be 
obtained. In total, 19 different sequence types (STs) were identified (Figure 1). Sixteen 
occurred only once and three (ST1684, ST1710 and ST1832) were novel sequence types. The 
most commonly identified STs were ST963 (three isolates), ST88 (two isolates) and ST1670 
(two isolates). With the exception of the three ST963 isolates, which all carried blaCMY gene, 
no association with ST and specific blaCTX-M or blaCMY genes was evident.  The two isolates 
that carried blaCTX-M-15 were found to be ST410 and ST448.    
3.6. Risk factors associated with carriage of AMR E .coli 
Univariable analysis identified a variety of explanatory variables to be significantly 
associated with one or more of the four outcomes tested. Any explanatory variables with a p-
value of less than 0.3 were included in the initial multivariable model (Supplementary tables 
1 to 4). With the exception of being fed raw poultry, which was significantly associated with 
ESBL carriage (P<0.001), fluoroquinolone resistance (P<0.001) and MDR (P=0.006), no 
variables were associated with more than one of the outcomes. 
Following sequential removal of variables from the maximal model, Table 3 shows the 
variables remaining in the models of the four outcomes. Raw poultry consumption remained 
significantly associated with ESBL carriage (OR 48.04), fluoroquinolone resistance (OR 
2.18) and MDR (OR 4.11). There was evidence of an interaction between raw poultry 
consumption and being a working dog in the fluoroquinolone resistance model with working 
dogs that also consumed raw poultry being 104 times more likely to carry an E. coli that was 
resistant to fluoroquinolones, however confidence intervals were wide. Breed size was 
identified as a risk factor for ESBL carriage and MDR. For ESBL mediated resistance with 
large dogs eight times more likely to carry ESBL producing E. coli compared to 
small/medium dogs. In the MDR model, large dogs were 2.5 times more likely to carry MDR 
E. coli than medium sized dogs with no significant difference between small and medium 
dogs. Other variables that remained in the final models included antimicrobial prescription, 
presence of or contact with other animals, age and the purpose of the veterinary consultation, 
though none were associated with more than one of the four models.  
4. Discussion  
This study investigated the prevalence faecal carriage of AMR E. coli by vet visiting dogs in 
the UK. Plasmid mediated AmpC β-lactamase-producing E. coli carriage was higher (7.1%) 
than the prevalence of ESBL producing E. coli (1.9%). However, only one gene variant 
associated with the AmpC β-lactamase phenotype (blaCMY-2) was identified, which has been 
identified in E. coli from canine clinical samples in Italy and Canada (Carattoli et al., 2005; 
Sanchez et al., 2002), and healthy dogs from many countries including the USA and the UK 
(Murphy et al., 2009; Wedley et al., 2011). The high frequency of this gene in canine isolates 
may be due to spread of a few specific plasmids (Hopkins et al., 2006), or the integration of 
the blaCMY-2 gene into many plasmids facilitating widespread dissemination (Carattoli et al., 
2002). There was a greater clustering of pAmpC carriage (19.9%, the degree of clustering) 
within practice compared to other outcomes (with the exception of ESBL carriage, 53.53%), 
which supports the suggestion that prescribing practices (Hughes et al., 2012), or other 
practice specific factors, may have a direct effect of carriage of AMR bacteria.  
This study found carriage of AMR E. coli to be common among the vet-visiting dogs (44.8%) 
with resistance to ampicillin, tetracycline and trimethoprim most prevalent, reflecting 
previous studies (Costa et al., 2008; SVARM, 2006), which may be attributed to the 
numerous determinants responsible for resistance and that they are readily transmissible, but 
also the frequent use of these and related drugs in dogs .  
Resistance to other antimicrobials in this study appeared to be higher than previously 
reported (Carattoli et al., 2005; Costa et al., 2008; Murphy et al., 2009; Wedley et al., 2011). 
This may be due to the type of population; for example these were vet-visiting dogs, some of 
which reported recent antimicrobial use, while other studies recruited community dogs and/or 
excluded animals with any history of antimicrobial use. MDR isolates were found in 18.4% 
of dogs; however, it is difficult to compare this with other studies since the definition of 
MDR differs between studies. 
Microarray analysis of antimicrobial resistance genes showed that many isolates harboured 
genes encoding resistance to a wide range of antimicrobials, including sulphonamides (sul2), 
aminoglycosides (aadA1, strA) and chloramphenicol (catA1). These AMR genes are also 
commonly identified in isolates of human origin (Card et al., 2015; Frye et al., 2006; 
Kirchner et al., 2014). Furthermore, the predominant genes and mechanisms of resistance for 
each of the antimicrobials concur with other studies of resistance genes in canine isolates 
(Costa et al., 2008; Lanz et al., 2003). This provides further evidence that antimicrobial 
resistance in bacteria isolated from dogs is often mediated by the same genes as those of 
human origin. Whilst microarray analysis was only carried out on a subset of the isolates, 
there was strong evidence co-carriage of different resistance genes. Plasmids are known to 
carry numerous resistance genes and so the presence of correlation of gene carriage is to not 
unexpected.  
A wide variety of genes associated with virulence were also detected, but by far the most 
commonly identified were those associated with extra-intestinal pathogenic E. coli (ExPEC) 
including iss and iroN (Johnson et al., 2008c; Russo et al., 2002). However, the microarray 
chip did not include the specific genes that have been suggested as being markers of ExPEC 
(at least two of the five virulence markers: papA and papC, sfa/foc, afa/dra, iutA, 
and kpsMT II), (Johnson et al., 2001). Dogs have been suggested as a potential reservoir for 
the ExPEC pathotype (Johnson et al., 2008b). It is also interesting to note that some isolates 
harboured virulence genes associated with the locus of enterocyte effacement (LEE) found in 
enteropathogenic E. coli (EPEC) and enterohemorrhagic E. coli (EHEC) (Kaper et al., 2004). 
Dogs often eat faeces of livestock, which are carriers of EHEC, furthermore a previous study 
found coprophagy to be a risk factor for antimicrobial resistance in canine faecal samples 
(Leite-Martins et al., 2014).  
Many of the STs identified have previously been identified in both clinical and non-clinical 
samples from humans, dogs and other animals from within the UK, other parts of Europe and 
as far as Canada and Australia (http://mlst.warwick.ac.uk/mlst/dbs/Ecoli/GetTableInfo_html). 
For example, ST10 has been reported in the UK, Africa, Europe, South America and the USA 
in samples from humans, dogs and livestock. Recently,  a new human clone has been reported 
(Schaufler et al., 2016), which has also been identified in veterinary clinical isolates in the 
UK (Timofte et al., 2016), with an isolate of the same ST (ST410) resistant to 
fluoroquinolones and carrying blaCTX-M-15 found in this study.  Typing of more isolates with a 
diverse range of resistance phenotypes may enable better links between ST, virulence and 
resistance to be investigated further. There was a high degree of diversity among ESBL and 
AmpC β-lactamase-producing isolates in this study, demonstrating that such E. coli show 
highly variable antimicrobial resistance, virulence and sequence types, but overall was 
similar to that observed in human isolates.   
This study determined some risk factors associated with carriage of AMR E. coli in the UK 
dog population. The finding that administration of antimicrobials within the last 3 months 
was associated with AMR E. coli carriage in two of the final models is not surprising given 
the selection pressure this would exert upon commensal bacteria. Previous studies found that 
the administration of fluoroquinolones and β-lactams were associated with an increased risk 
of carriage of AMR E. coli in dogs (Gibson et al., 2011; Leite-Martins et al., 2014). Further 
work in this area may provide greater understanding of the effects of short and long term 
antimicrobial use on the gut flora, selection and carriage of resistant bacteria in dogs.  
Eating raw poultry was also identified as a risk factor in the final model of two of the three 
outcomes tested. This was also identified in a study investigating AMR E. coli in faecal 
samples from Labrador retrievers (Schmidt et al., 2015). Chickens have been identified as a 
potential reservoir for resistant bacteria and determinants (Costa et al., 2009) and it is 
possible that ingestion of raw poultry results in transfer of these. This is also supported by 
five of the ten isolates positive for blaCTX-M carrying blaCTX-M-1, which has been identified as 
the most common gene variant present in isolates of poultry origin (Efsa, 2011). Furthermore, 
a study in the Netherlands observed a high prevalence of ESBL carriage in raw food 
(Overdevest et al., 2011), demonstrating an increased risk of carriage of AMR bacteria when 
dogs consume raw meat.  
Limitations in this study may include the method of recruitment and selection bias, for 
example, during busy periods owners may not have been approached and case selection was 
based on a non-random convenience population. This cross sectional study gives the 
prevalence of carriage of AMR E. coli at a single time point, and it may be possible that this 
is transient in nature. A study in the Netherlands (Baede et al., 2015), repeatedly sampled 38 
dogs over six months and  found that many of the dogs demonstrated a high degree of 
variation between faecal shedding of AmpC and ESBL producing E. coli. Repeated sampling 
may represent a more accurate method to determine faecal shedding by dogs. Breed size also 
remained significantly associated with ESBL producing and MDR E. coli. However, the 
breed size of 161 dogs was not specified either because the owners did not specify the breed 
of their dog, or the dog was a cross breed and the size could not be determined.  
In conclusion, many of the dogs sampled harboured AMR E. coli. The potential for dogs to 
act as reservoirs for AMR bacteria and determinants has implications for public health. The 
welfare of the individual dogs could also be affected if this restricts future treatment options. 
In addition, knowledge of potential risk factors associated with the carriage of antimicrobial 
E. coli by dogs in the community will allow better risk management.  Educating owners on 
the risks of raw food diets comprising poultry meat and regulation of the process in addition 
to ensuring the prudent use of antimicrobial by veterinary surgeons would be a good place to 
begin. 
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8. Figure Legends 
 
Figure 1. Heat-map analysis the presence of antimicrobial resistance genes among 
ESBL and AmpC β-lactamase producing E. coli from canine faecal samples by DNA 
micro array. Black indicates that the isolate was positive for the gene. 
 
A - Quinolone resistance, B - Sulphonamides, C - Tetracyclines, D - Aminoglycosides, E - 
Chloramphenicol, F - Trimethoprim, G - β-lactams, H - Erythromycin, I - Streptogrammin, 
ST – Multi-locus sequence type. 
 
Supplementary figure F1. Correlation matrix of antimicrobial resistance genes 
identified in E. coli isolated from vet visiting canine faecal samples. 
 
A - Quinolone resistance, B - Sulphonamides, C - Tetracyclines, D - Aminoglycosides, E - 
Chloramphenicol, F - Trimethoprim, G - β-lactams, H - Erythromycin, I - Streptogrammin, 
ST – Multi-locus sequence type. 
  
 Table 1. Prevalence of antimicrobial resistant E. coli isolated from 581 canine faecal 
samples. 
 Sample 
prevalence %  
(95% confidence 
interval) n=580 
Adjusted 
prevalence* % 
(95% confidence 
interval 
ICC 
Any resistance 44.8% (40.8-48.9) 44.7% (40.1-49.4) 3.07 
Multidrug resistance 18.3% (15.1-21.4) 17.6% (14.1-21.4) 5.02 
Ampicillin 37.2% (33.3-41.2) 36.9% (32.2-41.9) 5.57 
Amoxicillin/clavulanic 
acid 
7.1% (5.0-9.2) 6.6% (4.3-10.0) 5.21 
Chloramphenicol 9.1% (6.8-11.5) 8.0% (5.5-11.6) 10.62 
Ciprofloxacin 5.0% (3.2-6.8) 5% (3.5-7.1) 0 
Nalidixic acid 7.9% (5.7-10.1) 7.9% (6.0-10.4) 0 
Tetracycline 30% (26.3.-33.7) 28.9% (24.3-33.9) 7.54 
Trimethoprim 23.8% (20.3-27.3) 23.2 (19.5-27.5) 4.03 
ESBL mediated 
resistance 
1.9% (0.8-3.0) 0.5% (0.1-3.3) 53.53 
AmpC mediated 
resistance 
7.1% (5.0-9.2) 5.1% (3.0-8.8) 19.93 
*Estimates adjusted for clustering within practice 
  
Table 2. Genes detected and AMR phenotype in 52 ESBL or AmpC producing E.coli 
isolates from canine faecal samples. 
Genes detected Row Labels Count of 
Full profile 
blaCMY2 Amp, 1st Gen 1 
blaCMY2 Amp, 1st Gen, 2nd Gen 1 
blaCMY2 Amp, Amc, 1st Gen 2 
blaCMY2 Amp, Amc, 1st Gen, 2nd Gen 1
7 
blaCMY2 Amp, Amc, 1st Gen, 2nd Gen, 3rd Gen 3 
blaCMY2 Amp, Amc, Tet, 1st Gen, 2nd Gen 3 
blaCMY2 Amp, Atm, Sxt, 1st Gen, 2nd Gen, 3rd Gen 1 
blaCTX-M-1 Amp, Tet, 1st Gen, 2nd Gen, 3rd Gen 1 
blaCTX-M-1 Amp, Tmp, Sxt, 1st Gen, 2nd Gen 1 
blaTEM, blaCMY2 Amp, Amc, 1st Gen, 2nd Gen 3 
blaTEM, blaCMY2 Amp, Amc, 1st Gen, 2nd Gen, 3rd Gen 1 
blaTEM, blaCMY2 Amp, Amc, Atm, Cip, Nal, Tmp, Sxt, Tet, Chl, 
1st Gen, 2nd Gen, 3rd Gen 
1 
blaTEM, blaCMY2 Amp, Amc, Atm, Tmp, Sxt, Tet, 1st Gen, 2nd 
Gen, 3rd Gen 
1 
blaTEM, blaCMY2 Amp, Amc, Cip, Nal, Tmp, Sxt, Tet, 1st Gen, 
2nd Gen 
2 
blaTEM, blaCMY2 Amp, Amc, Cip, Nal, Tmp, Sxt, Tet, Chl, 1st 
Gen, 2nd Gen 
1 
blaTEM, blaCMY2 Amp, Amc, Cip, Nal, Tmp, Tet, 1st Gen, 2nd 
Gen 
1 
blaTEM, blaCMY2 Amp, Amc, Tet, 1st Gen, 2nd Gen 2 
blaTEM, blaCMY2 Amp, Amc, Tmp, Sxt, 1st Gen, 2nd Gen 1 
blaTEM, blaCMY2 Amp, Tmp, Sxt, 1st Gen, 2nd Gen 1 
blaTEM, blaCTX-M-1 Amp, Nal, Tmp, Sxt, Tet, Chl, 1st Gen, 2nd Gen 1 
blaTEM, blaCTX-M-1 Amp, Tmp, Sxt, Tet, 1st Gen, 2nd Gen 1 
blaTEM, blaCTX-M-1 Amp, Tmp, Sxt, Tet, Chl, 1st Gen, 2nd Gen 1 
blaTEM, blaCTX-M-14/18 Amp, Tmp, Sxt, Tet, Chl, 1st Gen, 2nd Gen 1 
blaTEM, blaCTX-M-15 Amp, Atm, Cip, Nal, Tmp, Sxt, Tet, 1st Gen2nd 
Gen3rd Gen 
1 
blaTEM, blaCTX-M-15 Amp, Cip, Nal, Tmp, Sxt, Tet, 1st Gen2nd Gen 1 
blaTEM, blaCTX-M-3 Amp, Tmp, Sxt, Tet, 1st Gen2nd Gen 1 
blaTEM, blaCTX-M-20 Amp, Tmp, Sxt, Tet, 1st Gen2nd Gen 1 
*1st Gen cephalexin, 2nd Gen cefuroxime/ cefoxitin, 3rd Gen ceftazidime/ ceftriaxone, Chl 
chloramphenicol, Mon aztreonam, Pen ampicillin/ amoxicillin/clavulanic acid, Q 
ciprofloxacin/ nalidixic acid, Tet tetracycline, Tm trimethoprim/ co-trimoxazole.  
  
Table 3. Multivariable model of variables associated with carriage of an ESBL (TEM or 
CTX-M), AmpC, Multi-drug resistant or fluoroquinolone resistant E. coli. Practice 
(n=73) was included as a random effect. 
 
  
AmpC 
mediated 
resistance  (565 
observations) 
ESBL mediated 
resistance 
(560 
observations) 
MDR  
(571 
observations) 
Fluoroquinolon
e resistance  
(538 
observations) 
Variable Response 
OR (95% 
CI) 
P-
Valu
e 
OR (95% 
CI) 
P-
Valu
e 
OR (95% 
CI) 
P-
Val
ue 
OR (95% 
CI) 
P-
Valu
e 
Prescribed 
any 
antibiotic in 
previous 
three 
months 
No Ref 
<0.0
01 
  
 
Yes 
5.99 
(2.92-
13.11) 
 
Other 
animals in 
the 
household 
No Ref 
0.03
9 
  
 
Yes 
0.46 
(0.20-
0.96) 
 
Fed raw 
poultry 
No 
 
Ref 
<0.0
01 
Ref 
0.0
04 
Ref <0.0
01 
Yes 
48.04 (8.83-
334.29) 
 
4.11 (1.59-
10.39) 
 
2.18 (0.32-
9.26) 
 
Neutered 
No 
 
Ref 
0.03
3 
 
 
Yes 
8.76 (1.17-
201.74) 
 
Breed size 
Small 
 
Ref (Small 
& Medium) 
0.01
6 
1.16 (0.48-
2.70) 
0.0
03 
 
Medium Ref  
Large 
8.32 (1.34-
162.71) 
 
2.48 (1.36-
4.76) 
 
Not 
specified 
0.93 (0.03-
25.95) 
 
1.04 (0.51-
2.12) 
 
Visited for 
Vaccination 
or worming 
No 
 
Ref 
0.03
3 
 
 
Yes 
0.37 (0.006-
0.87) 
 
In contact 
with other 
dogs during 
walks 
No 
 
Ref 
0.04
7 
  
Yes 
0.21 (0.045-
0.98) 
 
Visited with 
specific 
complaint 
No 
  
Ref 
0.0
20 
 
Yes 
1.73 (1.09-
2.79) 
 
Working 
dog 
No 
 
  
Ref 0.04
4 
Yes 
1.28 (0.29-
4.03) 
 
Age (years) <1    6.40 (1.06- 0.01
  
AmpC 
mediated 
resistance  (565 
observations) 
ESBL mediated 
resistance 
(560 
observations) 
MDR  
(571 
observations) 
Fluoroquinolon
e resistance  
(538 
observations) 
Variable Response 
OR (95% 
CI) 
P-
Valu
e 
OR (95% 
CI) 
P-
Valu
e 
OR (95% 
CI) 
P-
Val
ue 
OR (95% 
CI) 
P-
Valu
e 
55.5) 5 
1 to 2 Ref  
3 or more 
6.46 (1.55-
47.7) 
 
Sex 
Male 
 
  
Ref 0.01
6 
Female 
2.39 (1.17-
5.13) 
 
Medication 
prescribed 
during most 
recent visit 
No 
 
  
Ref 0.03
6 
Yes 
2.08 (1.05-4.16) 
Fed titbits 
Never/ 
rarely 
 
  
Ref 0.01
4 
Sometimes/ 
often 
2.17 (1.05-
4.99) 
 
Raw 
poultry:Wor
king dog* 
No raw 
poultry, not 
a working 
dog 
 
  
Ref 0.00
5 
Fed raw 
poultry and 
is a 
working 
dog 
37.49 
(2.74-
866.10) 
 
Practice Variance  
(standard deviation) 
ICC 
0.755 (0.869) 
18.66% 
0 (0) 
0.17(0.416) 
4.99% 
0(0) 
Deviance 221.41 66.67 491.47 252.04 
Degrees of freedom of 
model residuals 
561 552 564 
528 
P-value (Chi-squared) 1.000 1.00 0.987 1 
 
*Explanation of interaction term. No raw poultry not a working dog Odds ratio = 1.No raw 
poultry working dog Odds ratio = 1.28. Fed raw poultry not a working dog odds ratio = 2.18, 
Fed raw poultry and working dog Odds ratio = 1.28*2.18*37.49 = 104.61. 
 
  
 
